After nine years of grinding, Replit finally found its market. Can it keep it?

While AI coding startups like Cursor close brow-raising rounds on barely three years of existence, Replit's path to a $3 ...
Invezz

Tutorial price prediction: TUT price up 66% in 3 months, but how high can it go?

Tutorial platform has launched Learn Platform, Web3 domains, and gaming integration. TUT price analysis is bullish with RSI at 54.63 and strong volume. Binance spotlight boosts visibility but niche ...
WBOY

Replimune (REPL) Shares Tank 45% After Company Says No Pathway Identified For Lead Drug RP1, Securities Class Action Pending - Hagens Berman

On July 22, 2025, Replimune publicly announced that the U.S. Food and Drug Administration (FDA) had issued a "Complete Response Letter" (CRL) for its Biologics License Application (BLA) for RP1. This ...
Seeking Alpha

Replimune: Further Uncertainty Of RP1 Warrants Move To 'Hold' Rating

The last time I spoke about Replimune (NASDAQ:REPL) it was with respect to a Seeking Alpha article entitled "Replimune: Scope Goes Beyond That of RP1 Oncolytic Targeting For Melanoma." With respect to ...
Hosted on MSN

JP Morgan Downgrades Replimune Group (REPL)

Fintel reports that on September 19, 2025, JP Morgan downgraded their outlook for Replimune Group (NasdaqGS:REPL) from Neutral to Underweight. Analyst Price Forecast Suggests 110.57% Upside As of ...
Yahoo Finance

Replimune Provides Update Following Type A Meeting with FDA

WOBURN, Mass., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today ...
Krebs on Security

Self-Replicating Worm Hits 180+ Software Packages

At least 187 code packages made available through the JavaScript repository NPM have been infected with a self-replicating worm that steals credentials from developers and publishes those secrets on ...
KTLA

REPL Deadline: REPL Investors with Losses in Excess of $100K Have Opportunity to Lead Replimune Group, Inc. Securities Lawsuit Filed by The Rosen Law Firm

Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Replimune Group, Inc. (NASDAQ: REPL) between November 22, 2024 and July 21, 2025, both dates inclusive (the ...